



ASX Announcement

Visioneering Technologies, Inc. Appendix 4C and Cash Flow Report

Atlanta, Georgia, USA 31 July 2017: Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses has today released its Appendix 4C - Quarterly Cash Flow for the period ended June 30, 2017 (second quarter FY17).

In the first full quarter since listing, the company has booked sales revenue of US\$186,156, an increase of 65% on the previous quarter (US\$112,705). This was a particularly pleasing result as the growth was primarily attributable to organic growth in repeat ordering.

In addition, active accounts (optometrist offices that purchased during the quarter) increased by 109 to a total of 295. This increase is a result of the new sales hires made in Q4 2016, continuing to develop their accounts, as well as the 10 new sales force personnel, recruited shortly after the March IPO, completing their training and starting to acquire new customers in the field, as planned. New accounts are expected to start generating revenue from Q3 onwards.

Net operating cash outflow for the quarter was US\$3,449,000, reflecting the Company's inventory build and sales and marketing expansion. Cash receipts from customers for the quarter were US\$146,000 and end-of-quarter cash on hand was US\$23,394,000.

	Q2 FY17 (US\$)	Q2 FY16 (US\$)	Year on year % change	Q1 FY17 (US\$)	Quarter on Quarter % change
Sales Revenue	\$186,156	\$38,485	384%	\$112,705	65%
Active Accounts	295	80	269%	186	59%

Cash outflows are predicted to increase to approximately \$4.5M next quarter, in line with the company's previously communicated growth plans as it increases its head count and builds inventory to support its market expansion in the US.

"We are very pleased with the continued build of momentum in sales and new customers" said Dr Stehen Snowdy, CEO and Executive Director of Visioneering. "Our new sales team members, hired in April, are fully trained and engaged in the field, adding new customers and sales, on track with our expectations. In addition, our awareness among practitioners is expanding exponentially,

generating a high level of inbound solicitations. This is very encouraging for VTI's future and we are confident that continued expansion by the Company will be rewarded by strong demand and sales growth."

The Company's next class of sales personnel is expected to onboard and undergo training in 4Q 2017, and to start contributing to accounts and revenue late Q3 to early Q4 2017, consistent with our IPO plans.

CFO Appointment

The company is also pleased to announce the appointment of Mark Rapoport to the role of Chief Financial Officer (CFO). Mark will also take responsibility for HR, IT, and Logistics, and will assist in managing Investor Relations. Mark joins Visioneering with more than three decades of experience, with a successful track record of management in Finance, Accounting, HR, Supply Chain Management and Investor Relations.

His most recent position was Chief Financial Officer for Capsule Technologies SAS, a Private Equity funded provider of Medical Device Information System solutions. Prior to that, Mark's healthcare experience included President and CEO for Thomas, Thomas and Walsh, Inc., a venture-capital-funded provider of Medicaid eligibility services to hospitals; and COO and CFO for Landacorp, Inc., a Nasdaq-listed company providing medical management programs to hospitals and managed care organizations.

Investor Conference Call

Investors are invited to join a conference call on Tuesday 1 August 2017 9:15am AEST (Monday 31 July 7:15pm PDT) hosted by Visioneering Technologies CEO Stephen Snowdy.

To pre-register for the call please follow the link below:

<https://services.choruscall.com.au/diamondpass/vtvision-297276-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call.

Alternatively you can dial in using the details below at the scheduled call start time.

Conference ID: 297276

Participant Dial In Numbers

Australia Toll Free: 1 800 558 698

Australia Local: 02 9007 3187

New Zealand Toll Free: 0800 453 055

Hong Kong: 800 966 806

Singapore: 800 101 2785

United Kingdom: 0800 051 8245

United States: (855) 881 1339

United Kingdom: 0800 051 8245

US Local (New York): (914) 202 3258

US Local (Los Angeles): (909) 235 4020

For more information, please contact:

Company	Investor and media relations
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. VTI also sells and plans additional contact lens products.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that VTI expects or anticipates will occur in the future are forward-looking statements. These include, without limitation, VTI's future cash expenditure and growth in revenue and the number of customer accounts.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign ownership restrictions:

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.